Baird Financial Group Inc. Reduces Stock Position in Repligen Corporation $RGEN

Baird Financial Group Inc. decreased its position in Repligen Corporation (NASDAQ:RGEN) by 15.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 144,571 shares of the biotechnology company’s stock after selling 27,059 shares during the quarter. Baird Financial Group Inc.’s holdings in Repligen were worth $19,725,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in RGEN. NewEdge Wealth LLC grew its holdings in shares of Repligen by 5.3% during the fourth quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company’s stock worth $244,000 after buying an additional 75 shares in the last quarter. UMB Bank n.a. raised its holdings in Repligen by 13.8% in the 4th quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 92 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its stake in shares of Repligen by 0.3% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock worth $4,542,000 after purchasing an additional 100 shares during the period. Coldstream Capital Management Inc. boosted its holdings in shares of Repligen by 5.3% during the fourth quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company’s stock worth $326,000 after purchasing an additional 101 shares during the last quarter. Finally, Itau Unibanco Holding S.A. increased its stake in Repligen by 38.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 104 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Stock Up 0.3%

NASDAQ:RGEN opened at $165.18 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The company has a market capitalization of $9.32 billion, a price-to-earnings ratio of 226.27, a price-to-earnings-growth ratio of 3.01 and a beta of 1.05. Repligen Corporation has a one year low of $100.99 and a one year high of $188.73. The stock has a 50-day simple moving average of $158.22 and a 200 day simple moving average of $135.29.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The firm had revenue of $204.13 million for the quarter, compared to analysts’ expectations of $201.59 million. During the same quarter in the prior year, the firm posted $0.26 earnings per share. Repligen’s revenue for the quarter was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Sell-side analysts predict that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Insider Activity

In related news, CFO Jason Garland sold 733 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This represents a 3.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.60% of the company’s stock.

Analyst Upgrades and Downgrades

RGEN has been the topic of several research analyst reports. Evercore reissued an “outperform” rating and issued a $160.00 target price on shares of Repligen in a research report on Monday, July 6th. Zacks Research upgraded Repligen from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 30th. Wells Fargo & Company boosted their target price on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday, July 30th. Wolfe Research initiated coverage on shares of Repligen in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price target on the stock. Finally, Weiss Ratings upgraded shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 13th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Repligen presently has a consensus rating of “Buy” and an average target price of $168.57.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to develop and produce biologic drugs. Its products are designed to support key stages of biomanufacturing, including upstream processing, downstream purification, filtration, and process monitoring.

The company’s portfolio includes chromatography products, filtration and single-use systems, process analytics technologies, and recombinant proteins such as Protein A-based products.